Theravance Biopharma (NASDAQ:TBPH) Raised to “Strong-Buy” at Zacks Research

Theravance Biopharma (NASDAQ:TBPH) was upgraded by research analysts at Zacks Research from a “hold” rating to a “strong-buy” rating in a report released on Thursday,Zacks.com reports.

A number of other analysts have also recently issued reports on TBPH. Weiss Ratings reissued a “hold (c)” rating on shares of Theravance Biopharma in a research report on Thursday, January 22nd. BTIG Research reaffirmed a “buy” rating and set a $21.00 price target on shares of Theravance Biopharma in a research report on Friday. B. Riley Financial reiterated a “neutral” rating and issued a $14.00 price objective (down from $28.00) on shares of Theravance Biopharma in a research note on Wednesday, March 4th. HC Wainwright increased their price objective on Theravance Biopharma from $20.00 to $27.00 and gave the company a “buy” rating in a report on Monday, March 2nd. Finally, Oppenheimer lowered shares of Theravance Biopharma from an “outperform” rating to a “market perform” rating in a research report on Thursday, March 5th. Two analysts have rated the stock with a Strong Buy rating, two have assigned a Buy rating and three have given a Hold rating to the stock. Based on data from MarketBeat.com, Theravance Biopharma has a consensus rating of “Moderate Buy” and a consensus target price of $22.60.

Theravance Biopharma Price Performance

Shares of TBPH opened at $14.33 on Thursday. Theravance Biopharma has a 1-year low of $7.90 and a 1-year high of $21.03. The stock has a market cap of $726.10 million, a PE ratio of 7.06 and a beta of 0.17. The firm has a fifty day moving average price of $18.00 and a 200 day moving average price of $16.85.

Theravance Biopharma (NASDAQ:TBPH) last issued its quarterly earnings data on Wednesday, March 25th. The biopharmaceutical company reported $1.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.44 by $0.71. Theravance Biopharma had a return on equity of 18.55% and a net margin of 98.54%.The company had revenue of $45.89 million for the quarter, compared to analyst estimates of $43.09 million. As a group, equities analysts expect that Theravance Biopharma will post -1.09 EPS for the current fiscal year.

Insider Activity

In related news, SVP Rhonda Farnum sold 31,067 shares of the business’s stock in a transaction dated Monday, March 16th. The stock was sold at an average price of $13.96, for a total value of $433,695.32. Following the transaction, the senior vice president owned 232,699 shares in the company, valued at $3,248,478.04. The trade was a 11.78% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. 6.90% of the stock is currently owned by corporate insiders.

Institutional Trading of Theravance Biopharma

A number of hedge funds have recently added to or reduced their stakes in the stock. Mirae Asset Global Investments Co. Ltd. lifted its stake in shares of Theravance Biopharma by 26.5% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,462 shares of the biopharmaceutical company’s stock worth $46,000 after acquiring an additional 515 shares during the period. Tower Research Capital LLC TRC boosted its holdings in shares of Theravance Biopharma by 18.5% in the second quarter. Tower Research Capital LLC TRC now owns 5,013 shares of the biopharmaceutical company’s stock valued at $55,000 after acquiring an additional 781 shares in the last quarter. Creative Planning increased its stake in shares of Theravance Biopharma by 6.7% during the third quarter. Creative Planning now owns 13,450 shares of the biopharmaceutical company’s stock worth $196,000 after acquiring an additional 842 shares during the period. State of Wyoming raised its holdings in Theravance Biopharma by 5.7% during the second quarter. State of Wyoming now owns 18,928 shares of the biopharmaceutical company’s stock worth $209,000 after purchasing an additional 1,019 shares in the last quarter. Finally, The Manufacturers Life Insurance Company raised its holdings in Theravance Biopharma by 6.9% during the second quarter. The Manufacturers Life Insurance Company now owns 15,747 shares of the biopharmaceutical company’s stock worth $174,000 after purchasing an additional 1,020 shares in the last quarter. 99.10% of the stock is owned by institutional investors and hedge funds.

Key Headlines Impacting Theravance Biopharma

Here are the key news stories impacting Theravance Biopharma this week:

• Positive Sentiment: Company highlights and cash/milestone strength — Theravance reported record brand-level profitability for YUPELRI®, received milestone payments tied to sales, expects ~ $400M in cash at end-Q1 2026 with no debt, and announced cost-reduction targets to generate $60–$70M of annualized cash flow starting Q3 2026. Theravance Biopharma Reports Fourth Quarter and Full Year 2025 Financial Results
• Positive Sentiment: Analyst optimism — BTIG reaffirmed a buy rating and set a $21 price target (material upside from current levels), and Zacks upgraded TBPH to a Rank #1 (Strong Buy), supporting the short-term positive sentiment. Benzinga Zacks: Rating Upgrade to Strong Buy
• Neutral Sentiment: Mixed earnings coverage — company releases show strong non‑GAAP profitability and reported milestone-driven revenue, but media/analytics outlets are publishing differing EPS figures (reports vary between a beat and a miss depending on metric/adjustment). Investors should check the company filing for GAAP vs. non‑GAAP reconciliations. Press Release — Q4 and Full Year 2025 Results Zacks: Q4 Earnings and Revenues Lag Estimates
• Negative Sentiment: Pipeline setback and strategic review — management discontinued ampreloxetine after Phase 3 CYPRESS results, is implementing a restructuring, and has formed a Strategic Review Committee to evaluate options including a potential sale — these actions reduce near-term R&D upside and signal material change in corporate strategy. Zacks: Q4 Earnings and Revenues Miss; Ampreloxetine Scrapped
• Negative Sentiment: Insider selling — SVP Rhonda Farnum sold ~31,067 shares in mid‑March; while not definitive, the sale is being watched by investors as a near-term negative signal. InsiderTrades: SVP Sells Shares

About Theravance Biopharma

Theravance Biopharma is a biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines, primarily in the areas of respiratory disease, inflammatory and immunology, and rare disorders. The company develops small-molecule therapies designed to address unmet medical needs by targeting specific molecular pathways. Its lead marketed product, YUPELRI® (revefenacin) inhalation solution, is the first and only once-daily, long-acting muscarinic antagonist (LAMA) approved by the U.S.